On Tuesday, the stock has given a downward sloping channel breakout along with strong volume. Additionally, the stock formed a sizeable bullish candle on the breakout day, which adds strength to the breakout.

Domestic benchmark indices ended the day in a negative territory as Sensex closed at the level of 30,609.30, falling by 63.29 points, which is 0.21 per cent lower than its previous close. Nifty declined by 10.20 points or 0.11 per cent to settle at 9,029.05 levels.

The stock of Apollo Tyres Limited was picked by our Bollinger Band squeeze scanner, which suggests that the stock is near a consolidation breakout.

Bata India Limited (BIL) announced financial results for the quarter ending March 31, 2020. On a year-on-year consolidated basis, the revenue from operations decreased by nine per cent to Rs 620.5 crore in Q4FY20 as against Rs 680.23 crore in the same quarter last year. 

Indoco Remedies announced receipt of approval from United States Food and Drug Administration (USFDA) of its abbreviated new drug application (ANDA) for Succinylcholine Chloride injection USP multi‐dose vial.

According to the report, the fallout of COVID-19 crisis will be severe on Indian economy. The extended nationwide lockdown will exacerbate the economic downturn as the agency's estimate pegs the nominal GDP growth at 0.9 per cent for FY21 (FY20 forecast: 6.8 per cent).

The NCDs are proposed to be listed on wholesale debt market (WDM) segment of BSE and NSE. Besides, the interest payable on it is 8.8 per cent per annum

BSE Star MF, in its constant endeavour to simplify and provide end-to-end value-based services to the mutual fund industry has launched BSE eKYC services (Aadhaar & video KYC-based investor onboarding solution) w.e.f. today to provide seamless experience of onboarding investors.

Hardcastle Restaurants Pvt Ltd (HRPL), a master franchisee for West & South India operations of McDonald’s restaurants and a subsidiary of Westlife Development, has launched contactless take-out service in select cities, in compliance with local government regulations.

Integrated global pharmaceutical company, Glenmark announced that it is planning to start a new open-label study to test the combined efficacy of two anti-viral drugs namely, Favipiravir and Umifenovir as a potential COVID-19 treatment strategy.